These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 29132522)

  • 21. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Kelley CE; Brown AJ; Diehl AM; Setji TL
    World J Gastroenterol; 2014 Oct; 20(39):14172-84. PubMed ID: 25339805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease - current status and future directions.
    Demir M; Lang S; Steffen HM
    J Dig Dis; 2015 Oct; 16(10):541-57. PubMed ID: 26406351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic Fatty Liver Disease.
    Wang XJ; Malhi H
    Ann Intern Med; 2018 Nov; 169(9):ITC65-ITC80. PubMed ID: 30398639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic Fatty Liver Disease (NAFLD)--A Review.
    Karim MF; Al-Mahtab M; Rahman S; Debnath CR
    Mymensingh Med J; 2015 Oct; 24(4):873-80. PubMed ID: 26620035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne.
    Kosmidou M; Milionis H
    Minerva Endocrinol; 2017 Jun; 42(2):109-121. PubMed ID: 27990792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options.
    Milic S; Mikolasevic I; Krznaric-Zrnic I; Stanic M; Poropat G; Stimac D; Vlahovic-Palcevski V; Orlic L
    Drug Des Devel Ther; 2015; 9():4835-45. PubMed ID: 26316717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
    Crespo M; Lappe S; Feldstein AE; Alkhouri N
    Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APPROACH TO THE PATIENT WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Mikolašević I; Orlić L; Štimac D; Mavrinac V; Colić M; Ostojić D; Milić S
    Lijec Vjesn; 2016 May; 138(5-6):159-163. PubMed ID: 29182828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease.
    Hannah WN; Harrison SA
    Clin Liver Dis; 2016 May; 20(2):339-50. PubMed ID: 27063273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic.
    Roberts KK; Cochet AE; Lamb PB; Brown PJ; Battafarano DF; Brunt EM; Harrison SA
    Aliment Pharmacol Ther; 2015 Feb; 41(3):293-300. PubMed ID: 25521607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.
    Alkhouri N
    Expert Opin Investig Drugs; 2020 Feb; 29(2):115-116. PubMed ID: 31971024
    [No Abstract]   [Full Text] [Related]  

  • 35. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
    Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
    Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
    Ahmed A; Wong RJ; Harrison SA
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview.
    Marchisello S; Di Pino A; Scicali R; Urbano F; Piro S; Purrello F; Rabuazzo AM
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?
    Afdhal NH
    JAMA; 2012 Aug; 308(6):608-16. PubMed ID: 22760235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.
    Fargion S; Porzio M; Fracanzani AL
    World J Gastroenterol; 2014 Oct; 20(37):13306-24. PubMed ID: 25309067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease.
    Williams T
    FP Essent; 2015 Aug; 435():24-9. PubMed ID: 26280342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.